FP
JAZZ icon

Foundry Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Foundry Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$10.7M Buy
86,429
+81,337
+1,597% +$10.6M 0.57% 53
2024
Q4 		$627K Buy
5,092
+1,730
+51% +$204K 0.03% 231
2024
Q3 		$375K Buy
3,362
+331
+11% +$36.3K 0.02% 259
2024
Q2 		$323K Buy
+3,031
New +$333K 0.02% 271

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Foundry Partners's JAZZ Position: Q1 2025 in Review

Foundry Partners increased its Jazz Pharmaceuticals (JAZZ) stake by 1,597% in Q1 2025, buying an estimated $10.6M and bringing the position to 86,429 shares worth $10.7M. The position accounts for 0.57% of the portfolio, ranked #53.

Foundry Partners first reported a position in JAZZ in Q2 2024 and has held it in 4 quarters since. 550 funds tracked by Wall St. Rank hold JAZZ as of Q1 2025.

  • Foundry Partners held 86,429 shares of Jazz Pharmaceuticals worth $10.7M as of Q1 2025.
  • Foundry Partners bought 81,337 Jazz Pharmaceuticals shares in Q1 2025, an estimated $10.6M.
  • Jazz Pharmaceuticals made up 0.57% of Foundry Partners's portfolio in Q1 2025, its #53 holding.
  • Foundry Partners first reported a position in Jazz Pharmaceuticals in Q2 2024 and has held it in 4 quarters since.
  • 550 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2025.

Based on Foundry Partners's 13F filing for Q1 2025, filed 5 May 2025.